However, transcriptional profiling reveals downregulation of ER signaling and upregulation of immune-related pathways, suggesting that this subgroup might have a more immunogenic profile within the ER + HER2- breast cancer group [34, 35]. This evidence concerns the gene ERBB2 and breast carcinoma.